Literature DB >> 12042701

The role of MLL in hematopoiesis and leukemia.

Patricia Ernst1, Jing Wang, Stanley J Korsmeyer.   

Abstract

The MLL gene, also called HRX or ALL-1, was originally identified as a recurrent chromosomal translocation in particular subtypes of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML). Reciprocal rearrangements of the MLL gene are most common in infant ALL and secondary AML. Because of the unique association with infant leukemia and the intriguingly immature and mixed lineage phenotype of leukemic cells, the authors speculate that the wild-type MLL gene plays an important role early in the development of the hematopoietic system. This article reviews recent progress in understanding the function of the wild-type MLL protein, with particular consideration of potential functions within the developing hematopoietic system. Murine gain- and loss-of-function models have provided clues to the normal functions of MLL and altered functions of oncogenic MLL fusion proteins. Biochemical and genetic approaches using other model organisms have also elucidated mechanisms by which these functions are achieved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042701     DOI: 10.1097/00062752-200207000-00004

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  44 in total

1.  Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Authors:  Bernd B Zeisig; Tom Milne; María-Paz García-Cuéllar; Silke Schreiner; Mary-Ellen Martin; Uta Fuchs; Arndt Borkhardt; Sumit K Chanda; John Walker; Richard Soden; Jay L Hess; Robert K Slany
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  Histone 3 lysine 4 methylation during the pre-B to immature B-cell transition.

Authors:  Eric J Perkins; Barbara L Kee; Dale A Ramsden
Journal:  Nucleic Acids Res       Date:  2004-03-29       Impact factor: 16.971

3.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 4.  Conquering the complex world of human septins: implications for health and disease.

Authors:  E A Peterson; E M Petty
Journal:  Clin Genet       Date:  2010-02-11       Impact factor: 4.438

5.  Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies.

Authors:  Patrick A Zweidler-McKay; Yiping He; Lanwei Xu; Carlos G Rodriguez; Fredrick G Karnell; Andrea C Carpenter; Jon C Aster; David Allman; Warren S Pear
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

6.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

Review 7.  Roles of a trithorax group gene, MLL, in hematopoiesis.

Authors:  Ryoichi Ono; Tetsuya Nosaka; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

Review 8.  DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; A Thomas Look
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

Review 9.  Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective.

Authors:  Xinjiang Wu; Xianxin Hua
Journal:  Curr Mol Med       Date:  2008-12       Impact factor: 2.222

10.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.